Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. Provides £50 Million Extra For Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Extra funds made available in the U.K. for anti-cancers turned down by NICE, with a £200 million fund to be set up next year.

You may also be interested in...

Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE

NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.

Xolair’s Price Discount For NICE Is Ominous Sign For Older Products

Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.

End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE

Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts